Recent trends in siRNA delivery for treatment of colorectal cancer
siRNA delivery for treatment of colorectal cancer
Keywords:Colorectal cancer, MDR, Nanocarrier, siRNA
Colorectal cancer (CRC) is the third most widespread cancer in the world. Currently, chemotherapy is effective treatment for CRC. Major problem with chemotherapy is the acquired multi drug resistance (MDR). Recently, siRNA (small interfering RNA) therapeutics has getting more attention to overcome the MDR in cancer and in various diseases. siRNA is a 21-23 base pair double stranded RNA having ability to silence specific genes at post transcriptional level. But, clinical practice of siRNA delivery having limitation due to enzymatic degradation by serum nucleases resulting poor stability, poor cellular uptake at target site. Now a days, development of various nanocarriers for efficient delivery of siRNA is a most challenging and rapidly growing research area. In this review, we summarize, the potential of various nanocarriers such as polymeric nanoparticles, lipid-based nanoparticles, inorganic nanoparticles, layered double hydroxide nanoparticles for siRNA delivery in colorectal cancer treatment.
2. Chandran SP, Natarajan SB, Chandraseharan S, Shahimi MS: Nano drug delivery strategy of 5-fluorouracil for the treatment of colorectal cancer. Journal of Cancer Research and Practice 2017; 4:45- 48
3. Subudhi MB, Jain A, Jain A, Hurkat P, Shilpi S, Gulbake A, Jain SK: Eudragit S100 Coated Citrus Pectin Nanoparticles for Colon Targeting of 5-Fluorouracil, Materials 2015;8:832-849.
4. Kim HJ, Kim A, Miyata K, Kataoka K: Recent progress in development of siRNA delivery vehicles for cancer therapy. Advanced Drug Delivery Reviews 2016; 104: 61–7
5. Cisterna BA, Kamaly N, Choi W, Tavakkoli A, Farokhzad OC, Vilos C: Targeted nanoparticles for colorectal cancer Nanomedicine 2016 ;11:2443-56.
6. Kabbinavar FF, Schulz J, Mccleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. 2005; 23 suppl16:3697–3705.
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004; 350 suppl 23:2335–2342
8. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II,randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003; 21 suppl 1:60–65.
9. Willett CG, Boucher Y, Di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004; 10 suppl 2:145–147.
10. Saltz LB, Clarke S, Diaz-Rubio E et al. : Bevacizumab in combination with oxaliplatin-based chemotherapy as first line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 2008; 26 suppl 12:2013–2019.
11. Giantonio BJ, Catalano PJ, Meropol NJ et al. : Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007; 25 suppl 12:1539–1544
12. Zahedi P, De Souza R, Huynh L, Piquette-Miller M, Allen C. : Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. Mol. Pharmaceut. 2011; 8 suppl 1:260–269.
13. Coley HM.: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev. 2008; 34 suppl 4 , 378–390.
14. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. :Rational siRNA design for RNA interference. Nat Biotechnol. 2004 Mar; 22 suppl 3:326-30
15. Vaishnaw AK, Gollob J, Vitalo GC, Hutabarat R, Sah D, Meyers R, FougerollesT, Maraganore J. : A status report on RNAi therapeutics. Silence 2010; 8 suppl 1:14.
16. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006; 2 suppl 12 :711-719.
17. Ku SH, Jo SD, Lee YK, Kim K, Kim SH- Chemical and structural modifications of RNAi therapeutics. Advanced Drug Delivery Reviews 2015; xxx–xxx
18. Lam JK, Chow MY, Yu Zhang. Susan WS Leung - siRNA Versus miRNA as Therapeutics for Gene Silencing, Therapy—Nucleic Acids 2015; 4, e252.
19. Wang S, Liu H, Pan LR, Zhang Y: Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia 2008 10, 399–407.
20. Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, et.al, :Molecular Mechanisms and Biological Functions of siRNA, Int J Biomed Sci 2017; 13 suppl 2: 48-57.
21. Kesharwani P, Gajbhiye V, Kumar Jain NK :A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012; 33:7138-7150.
22. Ofek P, Tiram G, Fainaro RS: Angiogenesis regulation by nanocarriers bearing RNA interference. Advanced Drug Delivery Reviews xxx (2017) xxx–xxx
23. Ross Wilson, Jennifer A. Doudna - Molecular mechanisms of RNA interference, Annu Rev Biophys. 2013; 42: 217–239.
24. Oh YK, Park TG: siRNA delivery systems for cancer treatment. Advanced Drug Delivery Reviews 2009; 61:850–862.
25. Wang J, Lu Z, Wientjes MG, Au JS: Delivery of siRNA Therapeutics: Barriers and Carriers. The AAPS Journal 2010; 12:
26. Akhtar S, Benter IF : Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 2007; 117:3623–3632.
27. Pecot CV, Calin GA, Coleman RL, Berestein GL, Sood AK: RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011; 11 suppl 1: 59–67.
28. Haussecker D.: Current issues of RNAi therapeutics delivery and development. Journal of Controlled Release (2014)
29. Li Y, Wang J, Wientjes MG, Au JL. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev. 2012; 64 suppl 1:29-39
30. Au JS, Yeung BZ, Wientjes MG, Lu Z: Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. Advanced Drug Delivery Reviews 2016; 97:280–301.
31. Ragelle H, Riva R, Vandermeulen G, Naeye B, Pourcelle V, Duff C.S et.al., : Chitosan nanoparticles for siRNA delivery: Optimizing formulation to increase stability and efficiency. Journal of Controlled Release 2014; 176:54–63.
32. Li L, Hu X, Zhang M, Ma S, Yu F, Zhao S et.al., : Dual Tumor-Targeting Nanocarrier System for siRNA Delivery Based on pRNA and Modified Chitosan. Mol Ther Nucleic Acids 2017; 8:169-183.
33. Zhao J, Feng S.S: Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. Nanomedicine (Lond.) 2015; 10 suppl 14:2199–2228.
34. Lee SY, Yang CY, Peng CL, Wei MF, Chen KC, Yao CJ, Shieh MJ: A Theranostic Micelleplex Co-delivering SN-38 and VEGF siRNA for Colorectal Cancer Therapy. Biomaterials 2016.
35. Svenson S, Case RI, Cole RO, Hwang J, Kabir SR, Lazarus D et.al., : Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical, Mol. Pharmaceutics 2016; 86:92-105.
36. Amjad MW, Amin MC, Katas H, Butt AM, Kesharwani P, Iyer AK: The in vivo anti-tumor activity of folate-conjugated cholic acid polyethylenimine micelles for the co-delivery of doxorubicin and siRNA to colorectal adenocarcinomas. Mol. Pharmaceutics 2015.
37. Raja MA, Katas H, Wen TJ: Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers. PLOS ONE 2015;10:1-19.
38. Al-Qadi S , Grenha A , López CR: Chitosan and its derivatives as nanocarriers for siRNA delivery. J. drug del. sci. tech 2012; 22 suppl 1:29-42.
39. Mishra DK, Balekar N, Mishra PK: Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy. Drug Deliv. and Transl. Res. 2017.
40. Siahmansouria H, Somia MH, Babalooc Z, Baradaranc B, Niaraghd FJ, Atyabie F et.al. :Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. Journal of Pharmacy and Pharmacology 2016.
41. Rudzinski WE, Adriana, Palacios, Abuzar, Ahmed, Michelle A. et.al.,: Targeted delivery of small interfering RNA to colon cancer cells using chitosan and PEGylated chitosan nanoparticles. Carbohydrate Polymers 2016; 147:323-32.
42. Lee SJ, Kim MJ, Kwon IC, Roberts TM: Delivery strategies and potential targets for siRNA in major cancer types. Advanced Drug Delivery Reviews 2016.
43. Xue HY, Guo P, Wen WC, Wong HL: Lipid-Based Nanocarriers for RNA Delivery. Current Pharmaceutical Design. 2015; 21:3140-314.
44. Li W, Szoka FC: Lipid-based Nanoparticles for Nucleic Acid Delivery. Pharmaceutical Research 2007; 24:438-448.
45. Tseng YC, Mozumdar S, Huang L: Lipid-based systemic delivery of siRNA. Advanced Drug Delivery Reviews 2009; 61:721–73.
46. Ding W, Wang G, Shao K, Wang F, Huang H, Ju S, Cong H, Wang H: Amelioration of Colorectal Cancer Using Negative Lipidoid Nanoparticles to Encapsulate siRNA Against APRIL by Enema Delivery Mode. Pathol. Oncol. Res. 2014.
47. Yamamoto S, Kato A, Sakurai Y, Hada T, Harashima H: Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. Journal of Controlled Release 2017.
48. Ding W, Wan F, Zhang J, Guo Y, Wang SJ: A novel local anti-colorectal cancer drug delivery system: negative lipidoid nanoparticles with a passive target via a size-dependent pattern. Nanotechnology 2013; 24.
49. Bochicchio S, Dapas B, Russo I, Ciacci C, Piazza O, Smedt SD et. al., :In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. Int J Pharm. 2017;525 suppl 2):377-387.
50. Aswathanarayan JB, Vittal RR, Muddegowda U: Anticancer activity of metal nanoparticles and their peptide conjugates against human colon adenorectal carcinoma cells. Artif Cells Nanomed Biotechnol. 2018; 46 suppl 7:1444-145.
51. Li L, Gu W, Chen J, Chen W, Xu ZP: Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles. Biomaterials. 2014; 35 suppl 10:3331-9.